Tags

Type your tag names separated by a space and hit enter

Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens.
J Clin Microbiol. 2003 Feb; 41(2):623-6.JC

Abstract

There is an increasing demand for diagnostic testing for Giardia intestinalis (G. lamblia) and Cryptosporidium parvum, with a priority being placed on obtaining diagnostic results in an efficient and timely manner. Several commercial companies have developed rapid diagnostic tests that are simple to perform and can be completed in less time than traditional methods for detecting Giardia and Cryptosporidium: We compared one of these rapid tests, the ImmunoCard STAT! (Meridian Bioscience, Inc.) lateral-flow immunoassay, with the MERIFLUOR direct fluorescent-antibody (DFA) test, the ProSpecT EZ microplate assay for Giardia and the ProSpecT microplate assay for Cryptosporidium, and modified Kinyoun's acid-fast stained smears for the detection of Cryptosporidium using 246 specimens. The MERIFLUOR DFA (Meridian Bioscience, Inc.) test detected the largest number of cases (32 Giardia and 37 Cryptosporidium) infections and was used to calculate the sensitivity and specificity of the other tests. For Giardia, the sensitivities of the ImmunoCard STAT! and the ProSpecT Giardia EZ microplate assay (Alexon-Trend, Inc.) were 81 and 91%, respectively. For detection of Cryptosporidium, the sensitivities of the ImmunoCard STAT!, the ProSpecT Cryptosporidium microplate assay (Alexon-Trend, Inc.), and modified Kinyoun's acid-fast stained smears were 68, 70, and 78%, respectively. Test specificities were equal to or greater than 99%. Specimens with very small numbers of organisms were not detected by the ImmunoCard STAT!, the ProSpecT microplate assay or modified Kinyoun's acid-fast stained smears.

Authors+Show Affiliations

Centers for Disease Control and Prevention, Public Health Service, Department of Health and Human Services, Atlanta, Georgia 30341-3724, USA. sjohnston@cdc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12574257

Citation

Johnston, Stephanie P., et al. "Evaluation of Three Commercial Assays for Detection of Giardia and Cryptosporidium Organisms in Fecal Specimens." Journal of Clinical Microbiology, vol. 41, no. 2, 2003, pp. 623-6.
Johnston SP, Ballard MM, Beach MJ, et al. Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens. J Clin Microbiol. 2003;41(2):623-6.
Johnston, S. P., Ballard, M. M., Beach, M. J., Causer, L., & Wilkins, P. P. (2003). Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens. Journal of Clinical Microbiology, 41(2), 623-6.
Johnston SP, et al. Evaluation of Three Commercial Assays for Detection of Giardia and Cryptosporidium Organisms in Fecal Specimens. J Clin Microbiol. 2003;41(2):623-6. PubMed PMID: 12574257.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens. AU - Johnston,Stephanie P, AU - Ballard,Melissa M, AU - Beach,Michael J, AU - Causer,Louise, AU - Wilkins,Patricia P, PY - 2003/2/8/pubmed PY - 2003/5/3/medline PY - 2003/2/8/entrez SP - 623 EP - 6 JF - Journal of clinical microbiology JO - J. Clin. Microbiol. VL - 41 IS - 2 N2 - There is an increasing demand for diagnostic testing for Giardia intestinalis (G. lamblia) and Cryptosporidium parvum, with a priority being placed on obtaining diagnostic results in an efficient and timely manner. Several commercial companies have developed rapid diagnostic tests that are simple to perform and can be completed in less time than traditional methods for detecting Giardia and Cryptosporidium: We compared one of these rapid tests, the ImmunoCard STAT! (Meridian Bioscience, Inc.) lateral-flow immunoassay, with the MERIFLUOR direct fluorescent-antibody (DFA) test, the ProSpecT EZ microplate assay for Giardia and the ProSpecT microplate assay for Cryptosporidium, and modified Kinyoun's acid-fast stained smears for the detection of Cryptosporidium using 246 specimens. The MERIFLUOR DFA (Meridian Bioscience, Inc.) test detected the largest number of cases (32 Giardia and 37 Cryptosporidium) infections and was used to calculate the sensitivity and specificity of the other tests. For Giardia, the sensitivities of the ImmunoCard STAT! and the ProSpecT Giardia EZ microplate assay (Alexon-Trend, Inc.) were 81 and 91%, respectively. For detection of Cryptosporidium, the sensitivities of the ImmunoCard STAT!, the ProSpecT Cryptosporidium microplate assay (Alexon-Trend, Inc.), and modified Kinyoun's acid-fast stained smears were 68, 70, and 78%, respectively. Test specificities were equal to or greater than 99%. Specimens with very small numbers of organisms were not detected by the ImmunoCard STAT!, the ProSpecT microplate assay or modified Kinyoun's acid-fast stained smears. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/12574257/full_citation L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=12574257 DB - PRIME DP - Unbound Medicine ER -